Home > Insider Trading > Filing (0001209191-19-047314)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
921299	Fibrogen Inc	FGEN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1623238	B Thomas Neff	C/O Fibrogen, Inc. 409 Illinois St. San Francisco CA 94158	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-08-21	6,834	$2.90	2,356,578	No	4	M	Direct
Common Stock	Disposition	2019-08-21	18,400	$44.79	2,338,178	No	4	S	Direct
Common Stock	Disposition	2019-08-21	1,418	$44.81	45,656	No	4	S	Indirect	By Family Partnership
Common Stock	Acquisiton	2019-08-22	6,834	$2.90	2,345,012	No	4	M	Direct
Common Stock	Disposition	2019-08-22	17,100	$43.80	2,327,912	No	4	S	Direct
Common Stock	Disposition	2019-08-22	1,300	$44.73	2,326,612	No	4	S	Direct
Common Stock	Disposition	2019-08-22	1,418	$43.77	44,238	No	4	S	Indirect	By Family Partnership

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	S	Indirect	By Family Partnership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	By Family Partnership

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-08-21	6,834	$0.00	6,834	$2.90
Common Stock	Stock Option (Right to Buy)	Disposition	2019-08-22	6,834	$0.00	6,834	$2.90

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
184,536		2020-06-09	No	4	M	Direct
177,702		2020-06-09	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	20,000	Indirect	By Spouse
Common Stock	60,946	Indirect	See footnote

Footnotes

Shares sold pursuant to a 10b5-1 plan.
The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
Fully vested.